{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:13:13Z","timestamp":1793211193932,"version":"4.5.0"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Brown Emerging Infectious Disease Scholars (EIDS) program","award":["R25AI140490"],"award-info":[{"award-number":["R25AI140490"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This case report describes the development of Progressive Multifocal Leukoencephalopathy (PML) in a 72-year-old male with relapsed\/refractory multiple myeloma (RRMM), following a single dose of teclistamab amidst a COVID-19 infection. Shortly after starting teclistamab treatment, the patient developed symptoms, including fever, altered mental status, and right-sided paresis. A diagnosis of PML was confirmed through the detection of JC virus PCR in the cerebrospinal fluid. Our report emphasizes the occurrence of PML after only one dose of teclistamab and highlights teclistamab\u2019s potential for severe infectious complications, despite its promise in treating RRMM.<\/jats:p>","DOI":"10.3390\/curroncol31050202","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T03:34:19Z","timestamp":1715225659000},"page":"2670-2678","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient"],"prefix":"10.3390","volume":"31","author":[{"given":"Panos","family":"Arvanitis","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Gerry House 111, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8489-108X","authenticated-orcid":false,"given":"Dimitrios","family":"Farmakiotis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Gerry House 111, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Pelcovits","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Rhode Island Hospital, 593 Eddy Street, Gerry House 111, Providence, RI 02903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Khanam, R., Ashruf, O.S., Waqar, S.H.B., Shah, Z., Batool, S., Mehreen, R., Pachika, P., Roksana, Z., Rehman, M.E.U., and Anwer, F. (2023). The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review. Antibodies, 12.","DOI":"10.3390\/antib12020038"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: Latest updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1002\/ajh.27159","article-title":"Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report","volume":"99","author":"Zaja","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14740338.2023.2274420","article-title":"A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma","volume":"22","author":"Midha","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/CMAR.S372237","article-title":"Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody","volume":"15","author":"Pan","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1080\/10428194.2022.2113532","article-title":"T cell redirecting bispecific antibodies for multiple myeloma: Emerging therapeutic strategies in a changing treatment landscape","volume":"63","author":"Kazandjian","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: Importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Liu, T., Schwartz, T., Chebolu, A.P., Tsui, J.C., Bhatt, N., and Scoles, D. (2023). Teclistamab-Associated Sclerouveitis with Hypopyon. Retin. Cases Brief Rep.","DOI":"10.1097\/ICB.0000000000001449"},{"key":"ref_14","first-page":"e49192","article-title":"Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity","volume":"15","author":"Lutfi","year":"2023","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/QAD.0000000000003145","article-title":"Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6 months of combination antiretroviral therapy","volume":"36","author":"Hentzien","year":"2022","journal-title":"AIDS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: Current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1080\/10428194.2017.1292355","article-title":"Lenalidomide-associated progressive multifocal leukoencephalopathy","volume":"58","author":"Brigo","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ejh.13909","article-title":"Progressive multifocal leukoencephalopathy in multiple myeloma","volume":"110","author":"Hoeynck","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4103\/aian.aian_698_23","article-title":"The Connecting Link: A Case Report of the First Association of COVID-19 and Progressive Multifocal Leukoencephalopathy","volume":"26","author":"Varghese","year":"2023","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2023.09.020","article-title":"Progressive multifocal leukoencephalopathy triggered by COVID-19 in a previously asymptomatic person living with undiagnosed HIV infection","volume":"137","author":"Ferreira","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13365-021-00980-2","article-title":"Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia","volume":"27","author":"Borrelli","year":"2021","journal-title":"J. Neurovirol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10072-023-06609-y","article-title":"Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: A diagnostic challenge","volume":"44","author":"Rispoli","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1016377","DOI":"10.3389\/fneur.2022.1016377","article-title":"Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies","volume":"13","author":"Hatchwell","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11910-019-0988-x","article-title":"Cerebral Venous Thrombosis: An Update","volume":"19","author":"Ferro","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.crad.2015.03.014","article-title":"Intracranial involvement by multiple myeloma","volume":"70","author":"Lasocki","year":"2015","journal-title":"Clin. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2126456","DOI":"10.1001\/jamanetworkopen.2021.26456","article-title":"Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review","volume":"4","author":"Patel","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","article-title":"Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev."},{"key":"ref_35","unstructured":"Brust, J.C.M., McGowan, J.P., Fine, S.M., Merrick, S.T., Radix, A.E., Vail, R.M., Stevens, L.C., Hoffmann, C.J., and Gonzalez, C.J. (2021). Management of Immune Reconstitution Inflammatory Syndrome (IRIS)."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/QCO.0b013e32832d7aff","article-title":"Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients","volume":"22","author":"Sun","year":"2009","journal-title":"Curr. Opin. Infect. Dis."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/5\/202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:23Z","timestamp":1760107343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/5\/202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["curroncol31050202"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31050202","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}